☰

cached image

Christopher Oermann, M.D. - Publications

Affiliations: 
Children's Mercy Hospital, Kansas City, KS, United States 
Tree Info Similar researchers PubMed Report error

31 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Stephenson KG, Lingle AJ, Baumberger KA, Dellon EP, Esther CR, Meier EM, Oermann CM, Shenoy VK, Smith NR, Wimmer NS, Duehlmeyer SR, Kam CW, McKinzie CJ, Poisson MO, Elson EC. Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 37758535 DOI: 10.1016/j.jcf.2023.09.005  0.363
2020 Elson EC, Meier E, Oermann CM. The implementation of an aminoglycoside induced ototoxicity algorithm for people with cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. PMID 32811788 DOI: 10.1016/j.jcf.2020.08.002  0.44
2019 Elson EC, Mermis J, Polineni D, Oermann CM. Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. Clinical Medicine Insights. Circulatory, Respiratory and Pulmonary Medicine. 13: 1179548419842822. PMID 31019373 DOI: 10.1177/1179548419842822  0.418
2018 Ren CL, Morgan RL, Oermann C, Resnick HE, Brady C, Campbell A, DeNagel R, Guill M, Hoag J, Lipton A, Newton T, Peters S, Willey-Courand DB, Naureckas ET. Cystic Fibrosis Pulmonary Guidelines: Use of CFTR Modulator Therapy in Patients with Cystic Fibrosis. Annals of the American Thoracic Society. PMID 29342367 DOI: 10.1513/AnnalsATS.201707-539OT  0.41
2015 Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 111-9. PMID 25091537 DOI: 10.1016/J.Jcf.2014.06.003  0.487
2015 Tiddens H, De Boeck K, Clancy J, Fayon M, Arets H, Bresnik M, Derchak P, Lewis S, Oermann C. WS02.2 Aztreonam for inhalation solution (AZLI) for eradication of new onset Pseudomonas aeruginosa ( PA ) infection in children with cystic fibrosis (CF): Results of facemask vs. nebulizer mouthpiece use Journal of Cystic Fibrosis. 14: S3. DOI: 10.1016/S1569-1993(15)30008-4  0.345
2014 Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann CM, Ratjen F, Rosenfeld M, Simon RH, Hazle L, Sabadosa K, Marshall BC, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Annals of the American Thoracic Society. 11: 1640-50. PMID 25549030 DOI: 10.1513/Annalsats.201404-166Oc  0.478
2013 Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 12: 130-40. PMID 22985692 DOI: 10.1016/j.jcf.2012.07.006  0.332
2011 Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI). The Journal of Antimicrobial Chemotherapy. 66: 2398-404. PMID 21784781 DOI: 10.1093/Jac/Dkr303  0.391
2011 Pressler T, Assael B, Fischer R, Bresnik M, Lewis S, McKevitt M, Montgomery A, Oermann C. 107 In vitro susceptibility of Pseudomonas aeruginosa (PA) does not predict clinical response to aztreonam 75 mg powder and solvent for nebuliser solution (AZLI): a responder analysis in subjects with cystic fibrosis (CF) Journal of Cystic Fibrosis. 10: S27. DOI: 10.1016/S1569-1993(11)60124-0  0.326
2010 Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology. 45: 1121-34. PMID 20672296 DOI: 10.1002/Ppul.21301  0.447
2009 Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 135: 1223-32. PMID 19420195 DOI: 10.1378/Chest.08-1421  0.481
2009 Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Quittner A, Montgomery A. Adherence over multiple courses of Aztreonam Lysine for Inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60113-2  0.482
2009 McCoy K, Retsch-Bogart G, Gibson R, Oermann C, McKevitt M, Montgomery A. Efficacy of Aztreonam Lysine for Inhalation (AZLI) in patients with cystic fibrosis and drug resistant P. aeruginosa (DRPA) Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60112-0  0.345
2009 Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Montgomery A. Effect of multiple courses of Aztreonam Lysine for Inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Analysis of 18 month data from CP-AI-006 Journal of Cystic Fibrosis. 8: S28. DOI: 10.1016/S1569-1993(09)60111-9  0.449
2008 McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine. 178: 921-8. PMID 18658109 DOI: 10.1164/Rccm.200712-1804Oc  0.518
2008 Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatric Pulmonology. 43: 47-58. PMID 18041081 DOI: 10.1002/Ppul.20736  0.484
2008 McCoy K, Retsch-Bogart G, Gibson R, Oermann C, Braff M, Montgomery A. Microbiologic resistance and clinical efficacy of aztreonam lysine for inhalation (AZLI) in cystic fibrosis (CF) Journal of Cystic Fibrosis. 7: S36. DOI: 10.1016/S1569-1993(08)60138-1  0.439
2008 Oermann C, McCoy K, Retsch-Bogart G, Gibson R, Quittner A, Montgomery A. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): Interim analysis of 12 month data Journal of Cystic Fibrosis. 7: S25. DOI: 10.1016/S1569-1993(08)60097-1  0.47
2007 Garcia DF, Hiatt PW, Jewell A, Schoonover SL, Cron SG, Riggs M, Grace S, Oermann CM, Piedra PA. Human metapneumovirus and respiratory syncytial virus infections in older children with cystic fibrosis. Pediatric Pulmonology. 42: 66-74. PMID 17123316 DOI: 10.1002/Ppul.20546  0.307
2007 McCoy K, Retsch-Bogart G, Oermann C, Gibson R, Montgomery A. 40* Aztreonam lysine for inhalation (AZLI) for CF patients with P. aeruginosa (PA) infection Journal of Cystic Fibrosis. 6: S10. DOI: 10.1016/S1569-1993(07)60033-2  0.462
2006 Gibson RL, Retsch-Bogart GZ, Oermann C, Milla C, Pilewski J, Daines C, Ahrens R, Leon K, Cohen M, McNamara S, Callahan TL, Markus R, Burns JL. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatric Pulmonology. 41: 656-65. PMID 16703579 DOI: 10.1002/Ppul.20429  0.546
2005 Oermann CM, Al-Salmi Q, Seilheimer DK, Finegold M, Tatevian N. Mucinous cystadenocarcinoma of the pancreas in an adolescent with cystic fibrosis. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 8: 391-6. PMID 16010483 DOI: 10.1007/S10024-005-4114-5  0.316
2001 Oermann CM. Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. Current Opinion in Investigational Drugs (London, England : 2000). 2: 900-6. PMID 11757788  0.323
2001 Oermann CM, Sockrider MM, Giles D, Sontag MK, Accurso FJ, Castile RG. Comparison of high-frequency chest wall oscillation and oscillating positive expiratory pressure in the home management of cystic fibrosis: a pilot study. Pediatric Pulmonology. 32: 372-7. PMID 11596162 DOI: 10.1002/Ppul.1146  0.317
2000 Oermann CM. Fertility in patients with cystic fibrosis. Chest. 118: 893-4. PMID 11035652  0.419
2000 Janahi IA, Maciejewski SR, Teran JM, Oermann CM. Inhaled morphine to relieve dyspnea in advanced cystic fibrosis lung disease. Pediatric Pulmonology. 30: 257-9. PMID 10973044 DOI: 10.1002/1099-0496(200009)30:3<257::Aid-Ppul10>3.0.Co;2-R  0.346
2000 Oermann CM, Swank PR, Sockrider MM. Validation of an instrument measuring patient satisfaction with chest physiotherapy techniques in cystic fibrosis. Chest. 118: 92-7. PMID 10893365 DOI: 10.1378/Chest.118.1.92  0.303
1999 Oermann CM, Sockrider MM, Konstan MW. The use of anti-inflammatory medications in cystic fibrosis: trends and physician attitudes. Chest. 115: 1053-8. PMID 10208207 DOI: 10.1378/Chest.115.4.1053  0.336
1999 Murry DJ, Kearns GL, Oermann C, Gaedigk A, Sockrider M, Seilheimer DK, Leeder JS. CYP2C9 genotype and ibuprofen (IBU) pharmacokinetics (PK) in cystic fibrosis (CF) Clinical Pharmacology and Therapeutics. 65: 140. DOI: 10.1016/S0009-9236(99)80092-7  0.444
1997 Oermann CM, Starke JR, Seilheimer DK. Pulmonary disease caused by Mycobacterium kansasii in a patient with cystic fibrosis. The Pediatric Infectious Disease Journal. 16: 257-9. PMID 9041615 DOI: 10.1097/00006454-199702000-00021  0.417
Show low-probability matches.